An Observational Post-Authorization Modified Prescription-Event Monitoring Safety Study to Monitor the Safety and Utilization of Asenapine (Sycrest) in the Primary Care Setting in England

Trial Profile

An Observational Post-Authorization Modified Prescription-Event Monitoring Safety Study to Monitor the Safety and Utilization of Asenapine (Sycrest) in the Primary Care Setting in England

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Asenapine (Primary)
  • Indications Bipolar I disorders; Psychotic disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2016 Planned End Date changed from 1 Jan 2017 to 1 May 2017.
    • 27 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jan 2017.
    • 25 Jan 2016 Planned end date changed from 1 Jan 2016 to 1 Jan 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top